好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

IL33 - A Biomarker for Clinically Isolated Syndrome
MS and Related Diseases
S11 - (-)
001
MS is a clinically diagnosed disease and there are no sero- markers which will provide the clinician assistance in making the diagnosis or in predicting long term outcomes. Our preliminary studies performed using micro-arrays showed that the expression profile between MS patients at different stages of disease evolution was different. While the target profile within each clinical category of MS patients were similar, they however differed substantially between clinical subtypes. We explored this further by examining the expression profile of a panel of cytokine and interferon related genes in MS patients and healthy controls.
Blood samples were collected in PaxGene tubes. RNA was purified and cDNA synthesized using oligo-dT primers. Transcript levels were determined using TaqMan庐 gene expression assays by quantitative RT-PCR. Transcript levels were normalized to GAPDH.
Among the 43 cytokines and interferon mRNAs examined, IL33 was elevated in patients with CIS. The mean IL33 expression among 45 patients with CIS was 3000 percent greater than controls (p<0.001). When we examined expression of IL33 in newly diagnosed RRMS patients and in patients with established RRMS (on no therapy), the values were 300 percent greater than controls, P =0.03 and 0.01, respectively. These levels while significantly higher than controls were lower than that seen in CIS (p<0.01). IL-33 was not elevated in other neurological disease controls.
In the cross-sectional study, levels of IL-33 correlate with first onset of first demyelinating event. Progression to established RRMS is associated with decrease in IL33 levels when compared to the CIS group. Since IL33 belongs to the IL1 family, increased levels of IL33 may be an initial response of an innate immunity signal to a "danger signal".
Authors/Disclosures

PRESENTER 		No disclosure on file
Charles F. Spurlock III, PhD (Decode Health) Dr. Spurlock has received personal compensation for serving as an employee of Decode Health. Dr. Spurlock has received personal compensation for serving as an employee of New York University. Dr. Spurlock has received personal compensation for serving as an employee of IQuity Labs. Dr. Spurlock has stock in Decode Health. Dr. Spurlock has stock in IQuity Labs. The institution of Dr. Spurlock has received research support from National Institutes of Health.
Subramaniam Sriram, MD (Vanderbilt University Medical Center) Dr. Sriram has nothing to disclose.
Thomas M. Aune, PhD (Vanderbilt Rheumatology) No disclosure on file
Laura J. Balcer, MD, MSCE, FAAN (NYU Grossman School of Medicine) Dr. Balcer has received personal compensation for serving as an employee of North American Neuro-Ophthalmology Society. An immediate family member of Dr. Balcer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Children's Hospital of Philadelphia.